Nasdaq · Healthcare
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
As-reported financials and recent SEC filings for MADRIGAL PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$958.4M
Net income
$-288.3M
Net margin
-30.1%
Diluted EPS
$-12.85
ROE
-47.8%
P/E (TTM)
—
Market cap
$11.82B
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — |
| Operating income | $-300.1M | $-497.9M | $-380.5M | $-293.6M | $-242.5M |
| Net income | $-288.3M | $-465.9M | $-373.6M | $-295.4M | $-241.8M |
| Diluted EPS | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →42026-06-18
View on EDGAR →S-82026-06-17
View on EDGAR →8-K2026-06-17
View on EDGAR →Go deeper on MDGL
Search MADRIGAL PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.